Clinical Trial: Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus

U.S., July 2 -- ClinicalTrials.gov registry received information related to the study (NCT07677891) titled 'Phase II Study of Switching From Dulaglutide to PG-102(MG12) in Type 2 Diabetes Mellitus' on June 24.

Brief Summary: This is a randomized, open-label, multi-center, active-controlled Phase 2 clinical trial to evaluate the efficacy and safety of switching from once-weekly dulaglutide to PG-102(MG12) in patients with type 2 diabetes mellitus receiving stable dulaglutide therapy.

The treatment period is 32 weeks, with an additional 4-week safety follow-up. The primary endpoint is the change in HbA1c(%) from baseline at Week 32.

Study Start Date: Oct., 2026

Study Type: INTERVENTIONAL

Condition: Type 2 Diabetes

Intervention: DRUG: ...